Psycon Las Vegas: Navigating Tax Challenges in the Psychedelic Industry

At the recent PsyCon Convention in Las Vegas, Justin Botillier of Calyx CPA presented on taxation challenges within the cannabis and psychedelics industries, with particular focus on IRS Section 280E.

Understanding IRS Section 280E and Its Broad Implications

IRS Section 280E prohibits businesses involved with Schedule I or II controlled substances from deducting typical business expenses, except for the Cost of Goods Sold (COGS). This provision, implemented during the early 1980s war on drugs, creates substantial financial obstacles for affected businesses.

Insights for the Psychedelics Industry

The psychedelics sector faces comparable regulatory uncertainties and tax challenges as cannabis businesses. As this emerging industry develops, comprehending how tax statutes like 280E apply becomes essential for stakeholders.

Strategic Tax Planning for Cannabis and Psychedelics

Bifurcation Strategy: Separating operations into plant-touching and non-plant-touching entities can help optimize tax filings and reduce 280E impact.

Single Entity Strategy: Businesses maintaining unified operations require meticulous accounting to allocate costs properly and maximize allowable deductions.

IRC Section 471(c): A Tool for Compliance and Optimization

This provision offers flexibility in inventory cost accounting, enabling businesses to increase deductible COGS and mitigate 280E limitations.

Anticipating Future Legal and Regulatory Shifts

Botillier discussed potential policy changes and rescheduling efforts that could reshape how 280E applies to both industries.

The presentation emphasized engaging specialized tax professionals as regulatory environments continue evolving.